VEGFA and neoplasm: In the early stages of carcinogenesis, VEGF and its receptors are the main drivers of angiogenesis in the tumor, but in the process of tumor progression, other pathways are activated, leading to the development of bevacizumab (anti-VEGF drug) resistance [16,50,51].